EMLIRU Trademark

Trademark Overview


On Monday, April 9, 2018, a trademark application was filed for EMLIRU with the United States Patent and Trademark Office. The USPTO has given the EMLIRU trademark a serial number of 87868973. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 6, 2021. This trademark is owned by Eli Lilly and Company. The EMLIRU trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
emliru

General Information


Serial Number87868973
Word MarkEMLIRU
Filing DateMonday, April 9, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 6, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 4, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 18, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, December 6, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 6, 2021ABANDONMENT - NO USE STATEMENT FILED
Wednesday, April 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 6, 2021EXTENSION 5 GRANTED
Wednesday, March 31, 2021EXTENSION 5 FILED
Wednesday, March 31, 2021TEAS EXTENSION RECEIVED
Tuesday, September 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 21, 2020EXTENSION 4 GRANTED
Wednesday, September 16, 2020EXTENSION 4 FILED
Wednesday, September 16, 2020TEAS EXTENSION RECEIVED
Saturday, March 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 19, 2020EXTENSION 3 GRANTED
Thursday, March 19, 2020EXTENSION 3 FILED
Thursday, March 19, 2020TEAS EXTENSION RECEIVED
Friday, September 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2019EXTENSION 2 GRANTED
Wednesday, September 25, 2019EXTENSION 2 FILED
Wednesday, September 25, 2019TEAS EXTENSION RECEIVED
Friday, March 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 7, 2019EXTENSION 1 GRANTED
Thursday, February 28, 2019EXTENSION 1 FILED
Thursday, March 7, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 28, 2019TEAS EXTENSION RECEIVED
Tuesday, October 30, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 4, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 4, 2018PUBLISHED FOR OPPOSITION
Wednesday, August 15, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, July 26, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 26, 2018ASSIGNED TO EXAMINER
Wednesday, April 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 12, 2018NEW APPLICATION ENTERED IN TRAM